Immunogenicity and safety of co-administration of a recombinant shingles vaccine with an mRNA COVID-19 or adjuvanted influenza vaccine: a randomised controlled trial - PubMed
4 hours ago
- #vaccine co-administration
- #clinical trial
- #immunogenicity
- Co-administration of recombinant shingles vaccine (RZV) with mRNA COVID-19 or adjuvanted influenza vaccines shows non-inferior immunogenicity.
- Safety outcomes are low, with slightly higher rates of grade 3/4 systemic reactions in co-administration groups (max 3.3%).
- The study concludes that co-administration is safe and does not impair vaccine immunogenicity, supporting combined vaccination strategies.